Integra LifeSciences
IART
262 hedge funds and large institutions have $2.63B invested in Integra LifeSciences in 2023 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 80 increasing their positions, 114 reducing their positions, and 51 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
0.11% less ownership
Funds ownership: 84.43% → 84.33% (-0.11%)
7% less funds holding
Funds holding: 281 → 262 (-19)
8% less capital invested
Capital invested by funds: $2.85B → $2.63B (-$222M)
30% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 114
33% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 51
99% less call options, than puts
Call options by funds: $42K | Put options by funds: $3.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$47.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$38.1M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$28M |
| 4 |
PE
Point72 Europe
London,
United Kingdom
|
+$19M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$61.5M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$19.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$16.4M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$14M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.6M |
IART Hedge Fund Activity: Q3 2023 in Review
262 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q3 2023, worth a combined $2.63B — down 7.8% from $2.85B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of IART and 34 opened new positions — a net loss of 17 holders — while 114 trimmed existing stakes and 80 added.
The largest buyer was Deerfield Management, opening a new position worth an estimated $47.4M. The largest seller was Champlain Investment Partners, cutting an estimated $61.5M.
- 262 institutional investors held Integra LifeSciences (IART) as of Q3 2023, down from 281 in Q2 2023.
- Funds reported $2.63B of Integra LifeSciences stock for Q3 2023, down 7.8% quarter-over-quarter.
- 34 funds opened new Integra LifeSciences positions in Q3 2023 and 51 closed out, a net change of -17 holders.
- The largest Integra LifeSciences buyer in Q3 2023 was Deerfield Management, an estimated $47.4M added.
- The largest Integra LifeSciences seller in Q3 2023 was Champlain Investment Partners, an estimated $61.5M sold.
Based on aggregated 13F filings for Q3 2023.